Cargando…
Current Development of siRNA Bioconjugates: From Research to the Clinic
Small interfering RNAs (siRNAs) acting via RNA interference mechanisms are able to recognize a homologous mRNA sequence in the cell and induce its degradation. The main problems in the development of siRNA-based drugs for therapeutic use are the low efficiency of siRNA delivery to target cells and t...
Autores principales: | Chernikov, Ivan V., Vlassov, Valentin V., Chernolovskaya, Elena L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498891/ https://www.ncbi.nlm.nih.gov/pubmed/31105570 http://dx.doi.org/10.3389/fphar.2019.00444 |
Ejemplares similares
-
Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group
por: Petrova, Natalya S., et al.
Publicado: (2012) -
Structural Modifications of siRNA Improve Its Performance In Vivo
por: Chernikov, Ivan V., et al.
Publicado: (2023) -
Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene
por: Chernikov, Ivan V., et al.
Publicado: (2017) -
siRNA-Mediated Timp1 Silencing Inhibited the Inflammatory Phenotype during Acute Lung Injury
por: Chernikov, Ivan V., et al.
Publicado: (2023) -
Folate-Equipped Cationic Liposomes Deliver Anti-MDR1-siRNA to the Tumor and Increase the Efficiency of Chemotherapy
por: Gladkikh, Daniil V., et al.
Publicado: (2021)